A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
Latest Information Update: 01 Aug 2024
At a glance
- Drugs TSN 084 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Tyligand Bioscience
Most Recent Events
- 28 Apr 2024 Planned End Date changed from 30 Mar 2026 to 30 Jun 2026.
- 28 Apr 2024 Planned primary completion date changed from 30 Sep 2025 to 30 Dec 2025.
- 23 Apr 2024 Status changed from planning to recruiting.